Cushing's Syndrome Induced by Misuse of Moderate- to High-Potency Topical Corticosteroids

Abstract

Spanish

French

Objective:

To report a case of Cushing's syndrome caused by continuous use of moderate- to high-potency topical corticosteroids over several months.

Case Summary:

An 11-month-old patient with atopic dermatitis received uninterrupted treatment with moderate- to high-potency topical corticosteroids. He presented with several food allergies and was admitted to the hospital after atopic dermatitis worsened. Signs of growth retardation, which had begun at 6 months of age, were also noted during the child's hospital stay. An endocrinologist concluded that a lower-than-normal bone density scan and growth retardation on both weight and growth curves were due to suppression of the hypothalamic–pituitary–adrenal (HPA) axis and a multifactorial failure to thrive.

Discussion:

This is a case of an infant overexposed to topical corticosteroid treatment who developed Cushing's syndrome within a few months. Local treatment of atopic dermatitis is classically based on the use of topical corticosteroids in combination with an emollient or other drugs. To limit local and general damaging effects, the choice of topical corticosteroid must be made in terms of patient age, severity and site of the rash, and the extent of skin involvement. Several factors influence the systemic absorption of topical corticosteroids. While our literature review indicated the possibility of a multifactorial origin of the child's growth retardation, the use of topical corticosteroids was shown to have contributed to suppression of the HPA axis. Application of the Naranjo probability scale indicated a probable relationship between the continuous and sustained administration of topical corticosteroids over several months and suppression of the HPA axis. Although topical corticosteroids are widely used and can be perceived by parents and patients to be safe, daily documentation of agents used and body surfaces exposed should be done during long-term treatment.

Conclusions:

Continuous use of moderate- to high-potency topical corticosteroids over several months can contribute to Cushing's syndrome. Growth and development as well as cortisol levels should be monitored in children on long-term topical corticosteroid treatment.

Keywords

Cushing's syndrome growth retardation hypothalamic–pituitary–adrenal axis suppression topical corticosteroids

Get full access to this article

View all access options for this article.

References

Brown

, Reynolds

. Atopic and non-atopic eczema. BMJ 2006;332:584-8.

Abeck

, Strom

Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-6.

Granlund

Treatment of childhood eczema. Paediatr Drugs 2002;4:729-35.

Darsow

, Lübbe

, Taïeb

.; European Task Force on Atopic Dermatitis. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286-95.

Ohman

, Rogers

, Meenan

, McKenna

. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med 1987;80:422-4.

Gilbertson

, Spellman

, Piacquadio

, Mulford

. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998;38:318-21.

Gen

, Akbay

, Sezer

Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci 2007;333:173-4.

Abma

, Blanken

, De

Heide LJ

. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002;60:148-50.

Teelucksingh

, Bahall

, Coomansingh

, Suite

, Bartholomew

Cushing's syndrome from topical glucocorticoids. West Indian Med J 1993;42:77-8.

10.

Oelkers

Adrenal insufficiency. N Engl J Med 1996;335:1206-12.

11.

Furue

, Terao

, Rikihisa

. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003;148:128-33.

12.

Schafer-Korting

, Schmid

, Korting

. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 1996;14:375-85.

13.

Drake

, Dinehart

, Farmer

. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996;35:615-9.

14.

Hengge

, Ruzicka

, Schwartz

, Cork

. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15; quiz 16-8.

15.

Schnopp

, Holtmann

, Stock

. Topical steroids under wet-wrap dressings in atopic dermatitis—a vehicle-controlled trial. Dermatology 2002;204:56-9.

16.

Devillers

, Oranje

. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006;154:579-85.

17.

Rutter

Drug absorption through the skin: a mixed blessing. Arch Dis Child 1987;62:220-1.

18.

Turpeinen

, Lehtokoski-Lehtiniemi

, Leisti

, Salo

. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988;5:276-9.

19.

Mancini

. Skin. Pediatrics 2004;113:1114-9.

20.

Feldmann

, Maibach

. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967;48:181-3.

21.

Burks

Skin manifestations of food allergy. Pediatrics 2003;111:1617-24.

22.

Hill

, Sporik

, Thorburn

, Hosking

. The association of atopic dermatitis in infancy with immunoglobulin E food sensitization. J Pediatr 2000;137:475-9.

23.

Guillet

, Guillet

[Allergologic survey in 251 patients with moderate or severe dermatitis. Incidence and value of the detection of contact eczema, food allergy or sensitization to air-borne allergens] French. Ann Dermatol Venereol 1996;123:157-64.

24.

Agostoni

, Grandi

, Scaglioni

. Growth pattern of breastfed and nonbreastfed infants with atopic dermatitis in the first year of life. Pediatrics 2000;106:e73.

25.

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.

26.

Sharek

, Bergman

. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000;106:e8.

27.

Kristmundsdottir

, David

. Growth impairment in children with atopic eczema. J R Soc Med 1987;80:9-12.

28.

Naranjo

, Busto

, Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.

29.

Cherian

, AbdulJabbar

Cushing's syndrome and adrenal suppression from percutaneous absorption of clobetasol propionate in infants. Saudi Med J 2001;22:1139-41.

30.

Siklar

, Bostanci

, Atli

, Dallar

An infantile Cushing syndrome due to misuse of topical steroid. Pediatr Dermatol 2004;21:561-3.

31.

Ermis

, Ors

, Tastekin

, Ozkan

Cushing's syndrome secondary to topical corticosteroids abuse. Clin Endocrinol (Oxf) 2003;58:795-6.

32.

Güven

, Gülümser

, Ozgen

Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse?

J Pediatr Endocrinol Metab 2007;20:1173-82.

33.

Ozon

, Cetinkaya

, Alikasifoglu

, Gonc

, Sen

, Kandemir

Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007;20:219-25.

34.

Ellison

, Patel

, Ray

, David

, Clayton

. Hypothalamic–pituitary–adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-9.

35.

Haeck

, Timmer-de

Mik L

, Lentjes

. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Br J Dermatol 2007;156:979-85.